# Continuous Infusion of rhIL-15 for Adults With Advanced Cancer

> **NCT01572493** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 38 (actual)

## Conditions studied

- Lymphoma
- Carcinoma

## Interventions

- **BIOLOGICAL:** rh IL-15 (10 DAYS)
- **BIOLOGICAL:** rh IL-15 (5 DAYS)

## Key facts

- **NCT ID:** NCT01572493
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-04
- **Primary completion:** 2019-06-20
- **Final completion:** 2019-07-02
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01572493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01572493, "Continuous Infusion of rhIL-15 for Adults With Advanced Cancer". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT01572493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*